Formulation and Toxicity Evaluation of Nanostructured Lipid Carriers for the Treatment of Acne

Rita Lala* and Nikita Nandvikar

1Department of Pharmaceutics, Prin. K. M. Kundnani College of Pharmacy, Jote Joy Bldg, Ram Bhau Salgaonkar Marg, Cuff Parade, Colaba, Mumbai, 400005, India.

ABSTRACT

Background: Acne vulgarise is an inflammatory disease involving the pathological alteration of the sebaceous glands of the body. It is not a life-threatening disease but has a great influence on lifestyle. Topical combination therapy of vitamin A and antibacterial drugs is an effective treatment for acne.

Materials and Methods: The current work investigates the nanostructure lipid colloidal carrier system of Tretinoin and Clindamycin phosphate. Nanostructured lipid carriers (NLCs) were prepared by highspeed homogenization-sonication technique and characterized for physicochemical properties, permeation, in vivo anti-acne and toxicity (acute 2000 mg/Kg, repeat 1000 mg/kg) in Wistar rats.

Results: The prepared system was found to be stable, homogenous with more site retention of drugs having non-irritation and toxicity potential. The formulation showed a size of 283 nm, polydispersity index (PDI) 0.43 and Zeta potential (ZP) -37.9 mV with drug entrapment 92.0% and 66.15% for tretinoin and clindamycin respectively. Observed permeation was 18 % and 45% for Tretinoin and Clindamycin less than marketed formulation which is more focused on dermal retention of drug. No significant abnormalities and toxicological symptoms were observed for acute

Original Research Article
and repeat dose toxicity study for histopathology and haematological examinations of organs.

**Conclusion:** Prepared NLC formulation was aimed at epidermal targeting. Based on obtained results it is concluded that developed lipid-based nanocarrier system of selected drugs showed the targeting potential for effective acne treatment.

**Keywords:** Nanostructured lipid carriers; acute toxicity; repeat dose toxicity.

1. INTRODUCTION

Acne vulgaris is the most common, prevalent skin disease. A significant number of the population is affected by acne. It is not life-threatening but influences quality of life [1-3]. Acne patients exhibit low self-esteem owing to the diverse lesions on their face, chest and back. A common type of bacteria *Propionibacterium (P) acnes* contributes to acne by causing inflammation. It is an inflammation of sebaceous follicles, characterized by seborrhea, papules, comedones, nodules, pimples and pustules. Factors responsible for acne are sebum, hormones, follicular differentiation, bacteria *Propionibacterium acnes*, inflammation and nutrition [4, 5].

Many treatments exist such as retinoids, antibiotics, keratolytic, anti-seborrheic, anti-androgen medications and hormones-based treatment. Anti-bacterial such as clindamycin, erythromycin, minocycline, tetracycline, hydroxyquinoline and vitamin A derivatives such as tretinoin, isotretinoin, adapalene can be used [6-11]. Topical therapy of vitamin A which exhibits anti-comedolytic activity and antibacterial drug clindamycin phosphate is a better acne treatment [12-17]. Novel drug deliveries providing alternatives for enhanced impact as a drug is loaded in lipid carrier systems like nanocrystals [18,19], liposomes [20,21], niosomes [22], microemulsion [23], lipid nanoparticles [24, 25]. The first generation of solid lipid nanoparticles (SLN) were prepared from only solid lipid. The second-generation nanostructured lipid carriers (NLCs) are prepared by a mixture of solid, liquid lipid [26-33]. NLCs are also used as delivery carriers for hydrophobic and hydrophilic drugs, expected to have low toxicity and biodegradability.

Clindamycin phosphate (2mg/10 ml) is more water-soluble than tretinoin (< 0.1g/100mL). This work focuses on the incorporation of Clindamycin phosphate and Tretinoin into colloidal nanostructured lipid carrier formulation followed by characterization for morphology, entrapment efficiency, permeation, *in vivo* activity and toxicity potential. *In vivo* activities tested on Wistar rats. Dermal toxicity studies outcome is outlined in this article to characterize the skin irritation, local and systemic toxicity potential after dermal administration and evaluated as a better potential for acne treatment [34-36].

2. MATERIALS

Tretinoin was offered as a gift sample from Ranbaxy Pharmaceuticals, Delhi, India whereas Clindamycin phosphate was provided by SRS Pharma aqLTD. Mumbai, India. Cremophore EL was gifted by BASF, Mumbai. Shea butter was supplied by Anshul Pharmaceuticals, Mumbai. Emulcier 61 was gifted by Gattefossae Ltd, Mumbai, India. Olive oil, Jojoba oil was gifted by Aromax Pharma LTD. Mumbai, India. Stearic acid, Cetyl palmitate, Span 20, Span 80, PEG 200, Oleic acid, Medium chain triglycerides and other solvents used for analysis were purchase from S. D. Fine Chem. Mumbai, India. The remaining materials used were of analytical grade.

3. METHODS

3.1 Screening of Drug in Liquid Lipids and Surfactants

Drug solubility in selected liquid lipids (Jojoba oil, oleic acid, olive oil, medium chain triglycerides) and surfactants (Cremophore EL, Span 20, Span 80, PEG 200) was determined. The vials were filled with an excess quantity of drug and 2 ml of liquid lipid and surfactant. It was stirred to achieve equilibrium for 24 h at 25°C. Vials were then centrifuged using ultracentrifuge at 10,000 rpm, 30 min. The clear supernatant was collected and drugs were quantitated by U.V. Spectrophotometer. Tretinoin was determined using solvent methanol with suitable dilutions and analyzed at 339 nm whereas Clindamycin was evaluated using methanolic sodium hydroxide 0.1 N (1:1) at 215 nm after suitable dilutions [37,38].

3.2 Screening of Solid Lipids

Solid lipid solubility (stearic acid, Cetyl palmitate, Emulcier 61, Shea butter) was done by adding
both drugs (5 mg) in a wide-mouth, amber coloured, screw-capped bottle. The lipids were heated till melting. This molten lipid was added in a small portion. The addition of lipid is continued until no drug particle is seen visually. Lipid melt was quantified for Tretinoin by dissolving in methanol and for clindamycin phosphate in methanolic sodium hydroxide 0.1 N by using UV Spectrophotometer [39-41].

3.3 Preparation and Evaluation of NLCs

High-speed homogenization-sonication technique: Based on solubility screening of both the drugs in liquid, solid lipids and surfactants oleic acid, shea butter, Emulcier 61, Cremophor EL and Span 20 were selected for formulation preparation. Various batches with different proportions of both the lipids, surfactant and co-surfactant were prepared to select a suitable combination to get a stable batch.

Selected lipids were weighed and melted. Tretinoin was added to the hot, liquefied lipid phase. Clindamycin was dissolved in water (aqueous phase) and heated to emulsification temperature same to the oil phase. Both aqueous and lipid phase were mixed at a similar temperature around 60-70 °C using a magnetic stirrer, 2000 rpm, 10 min to prepare a stable primary emulsion and then with a high-speed homogenizer at 60,000 rpm, 20 min. This mixture was further processed by probe sonicator, 20 min to get NLCs. Obtained NLC formulation was of thick, creamy consistency. The prepared formulation was stored in an amber colour bottle for further evaluation [42-43].

Morphological evaluation: Particle size, zeta potential, polydispersity were evaluated using a Horiba particle size analyzer zeta sizer. Before size determination, suitable dilutions were with double distilled water. The diluted sample was evaluated at a fixed scattered angle of 173° and 25°C temperature [44-46].

% Entrapment Efficiency (EE): % EE of prepared NLCs was calculated by centrifugation. NLC formulation was diluted with equal parts of water and centrifuged at high-speed at 15,000 rpm, 30 min with a refrigerated centrifuge. The clear supernatant was separated and quantified for tretinoin by dissolving supernatant in methanol by U.V. Spectrophotometer at 339 nm and in methanolic sodium hydroxide 0.1 N at 215 nm for clindamycin [47].

% EE = (Drug added in the formulation – Unentrapped drug/ Drug added in the formulation) X 100

Drug permeation: A drug permeation was estimated using Franz diffusion assembly (12 ml capacity, 3.14 cm² area). Rat skin (Wistar rats, about 150-200 g) obtained from the college animal house. Hairs were removed using a hair trimmer and epilator cream and used as a diffusion membrane for study. The donor compartment consisted of 0.5 g of prepared NLCs formulation. The receptor chamber was filled with pH 7.4 phosphate buffer saline (PBS 7.4). The experiments were performed at temperature 37±0.5°C, 50 rpm. At pre-decided time interval of 0.5 h, 1 h, 2 h, 4 h, and 6 h, 0.5 ml aliquot from the receptor chamber was collected and replenished with an equal volume of media. Samples were analysed by spectrophotometer and the drug permeation profile was plotted to compared with marketed formulation [48].

Experimental animals: Wistar rat (200-250 g) species were used for in vivo anti-acne model and toxicity evaluation. The animals were acclimatized to laboratory conditions (25°C, 35-60% humidity).

3.4 In vivo Anti-acne Activity

Acne induction and treatment: A rat model was used to reflect the inflammation and acne genesis by injecting a culture of P. acnes. The lyophilized culture of bacteria P. acnes was procured from the Indian Institute of Microbial Technology (IMTECH), Chandigarh, India. Induction of acne was done by injecting heat-killed bacterial culture (60 °C for 30 min) of concentration 10³ CFU / ml, 20μl was injected to the right ear pinna subcutaneously for 4 days, once a day. Left ear pinna was without induction and considered as a control for comparison. Acne induction was identified by the presence of redness, inflammation and acne.

Acne on the right ear pinna. After induction animal ears were treated with the test formulation, marketed formulation and placebo formulation. Once a day 0.5 g of the formulation was applied to the affected area and observed for healing and any other changes [49].

3.5 In vivo Acute and Repeat Dose Toxicity Study

Acute dermal toxicity: The dermal toxicity was performed as per the OECD guidelines no.402
for the chemical testing. Wistar rats of 150-200 g were acclimatized to the laboratory condition for a week. Animals were assigned to the treatment and placebo groups. Each group contains 5 female and 5 male rats. A limit dose, 2000 mg/kg body weight was selected. Animals were shaved at the dorsal area before 24 h. About 10% of the body surface area was shaved for the test. Formulations were applied locally for 24 hrs on the first day of the study. Test substances were held in touch with the skin with a porous cotton dressing throughout the testing time. The test site of the animals was observed after 30 min, 2 h, 6 h, 24 h, 48 h, 72 h and 14 days. Animals were visually observed for mortality, morbidity, behaviour (salivation, convulsions, tremors, sleep, diarrheal, lethargy and coma, injury, changes in physical appearance, pain, signs of illness were conducted once daily during the study, as well as any changes in fur, mucous membrane, eyes) respiratory, circulatory, autonomic, nervous system were noted. Body weights were checked during the study [50].

Repeat dose toxicity study: Repeat dose toxicity test was performed according to the OECD guideline 410. Animals were divided into two groups treatment and placebo control consisting of 10 animals (5 females, 5 males). Animals were shaved before testing at the dorsal area. About 10 % of the body surface area was shaved for the application of the test substance. The test was performed at a limit dose of 1000 mg/kg body weight. The test substance was applied daily to the skin to the test and placebo control group for 6 h for a day for 28 days. The formulation was retained at a place by a non-adhesive bandage. The rat’s weight were noted and visually observed for mortality, morbidity, general behaviour same as the acute study. For histopathological evaluation animals were necropsied. Skin, liver, kidney and heart were isolated and stored in 10% formalin and processed for histopathology [51].

4. RESULTS AND DISCUSSION

4.1 Screening of Drug in Lipids and Surfactants

Both drug solubility in selected solid, liquid lipids and surfactants is predicted in Fig. 1 and Fig. 2. As per solubility studies, tretinoin and clindamycin exhibited maximum solubility in Emulcier 61(4.1 mg/g for tretinoin, 19.12 mg/ g for clindamycin phosphate), Oleic acid (18.63 mg/ml for tretinoin, 10 mg/ml for clindamycin phosphate), Span 20 (10.5 mg/ml for tretinoin, 4.5 mg/ml for clindamycin phosphate) and Cremophor EL (10.6 mg/ml for Tretinoin, 3 mg/ml for Clindamycin phosphate).

Selection criteria for lipids and surfactants for the development of tretinoin-clindamycin NLCs include pharmaceutical acceptability, non-irritation and sensitization potential and GRAS (generally regarded as safe) category. As per solubility studies, NLC was prepared using Emulcier, shea butter, as a combination of solid lipids, Oleic acid as liquid lipid and Span 20, Cremophor EL as a combination of surfactant and co-surfactant. Trial batches were prepared with selected solid, liquid lipid and surfactant co-surfactant combination to evaluate stability and suitability of selected ingredients for batch preparation [52-53].

4.2 Preparation of NLC

The solubility of tretinoin was observed more in Emulcier 61, shea butter, oleic acids and trial batches were observed to be more stable in presence of Span 20 and Cremophor. Table 1 represents the composition of a finalized batch obtained after various trials. The lipids were selected depending upon drug solubility and miscibility with each other. Prepared trial batches were evaluated for room temperature stability and particle size. The selected batch showed maximum stability and less particle size as compared to other prepared batches prepared by high speed homogenisation [54,55].

| Ingredients                  | % w/w |
|------------------------------|-------|
| Tretinoin                    | 0.05  |
| Clindamycin phosphate        | 0.1   |
| Oleic acid                   | 4     |
| Emulcier 61                  | 2     |
| Shea butter                  | 2     |
| Span 20                      | 7     |
| Cremophor EL                 | 3     |
| Water q. s.                  | 100   |

4.3 Characterization of NLCs

Morphological measurements: Particle size was found around 283 nm and zeta potential was -37.9 mv, polydispersity index 0.43 indicating a nano-size formulation with a stable behaviour. Fig. 3 represents the SEM image of NLC formulation. The SEM size was observed less than 100 nm size and of uniform spherical shape. From this data it is depicted prepared batch is of particle size (up to 200 nm) with good homogeneity, stable range zeta potential, thus represents a stable NLC system [56].
Entrapment efficiency: Observed entrapment for Tretinoin was 92.5% and for clindamycin phosphate was 66%. The entrapment efficiency (EE), is drug encapsulated inside or adsorbed over the surface of nano lipid core, was determined by estimating free Tretinoin and clindamycin in the supernatant. The lipids used for formulation solubilize the added Tretinoin. The encapsulation efficiency was found less for clindamycin as it is a hydrophilic nature. More drug is present in aqueous phase but surfactant co-surfactants help to entrapped it in colloidal lipid micelle by emulsification. Tretinoin is a fat soluble vitamin which is having more...
entrapment due to the lipoid nature and presence of surfactant co-surfactant combination [57].

**Drug permeation:** The present study is focused on the evaluation of topical target potential of the prepared system using Franz diffusion cell in PBS 7.4 at 37 °C, 50 rpm using cellophane membrane. The amount of both drugs permeated from prepared NLC formulation was determined and compared with marketed formulation for 6 hr is shown in Fig. 4. A higher release is observed for both the drugs of the hydrogel-based marketed formulation. The initial slow release may be due to un-entrapped drug of aqueous phase and some amount of drug adsorb on the lipid carrier surface. Tretinoin release is less as entrapment efficiency in lipid core is more as compared to Clindamycin which also suggests that release prolongation is due to entrapment in lipid core. The drug permeation for NLC is found less than marketed hydroalcoholic gel formulation. Less permeation of the drug through the skin for lipid-based formulation indicated more drug retention into the skin layer and less permeated across the skin. Retention of NLCs by the skin is due occlusive property and less diffusion through the skin which is desirable for site effective treatment. NLC based drug formulation is design for controlling the drug release as well as skin targeting [58,59].

**In vivo anti-acne rat model**

An inflammatory acne mouse model was used to evaluate an anti-acne activity of the prepared NLC formulation. Ear pinnae were observed daily for sign of acne and inflammation. After two to three days of induction micro-comedones and inflammation at injected left ear pinna were seen and compared to the uninfected right ear. Infection was treated with the marketed formulation and prepared NLC formulation once a day 0.5 g. Inflammation and acne signs disappeared after treatment with prepared NLCs formulation in two days where it required 3 days for the standard treatment group and required five days for the control group. Antiacne in vivo rat model images of rat ear pinna of a group A formulation test group, B standard treated group are shown in Fig. 5. Animals were infected by injecting heat-killed *P. acnes* culture into the animal ear pinna. Injected *P. acnes* induced the granulomatous inflammation followed by the formation of micro-comedones which is about mild to moderate type of acne. Smooth healing was observed for the test group as some scars were visible on the standard treatment group. The prepared formulation showed faster healing compared to the standard group. In vivo results suggested that prepared NLCs effectively treated bacterial infection and healed ear pinna better than marketed preparation [60].

![Drug permeation profile](image-url)
Fig. 5. Images of antiacne activity evaluation of prepared NLCs. Infected formulation test group a) day one c) day three, e) day five. Infected standard treated group b) day one, d) day three, f) day five

**Acute toxicity:** In acute dermal toxicity dose, 2000 mg/kg dose was found to be toxicologically insignificant. The treatment group did not show any toxicity sign on the surface of the skin at 24 and 48 h, 72 h after patch removal till 14 day, and the reaction was graded as “0” as per the Draize test score for erythema and oedema. No clinical signs of toxicity, mortality and changes in body weights were observed in treated animals. The treatment and placebo group did not show any changes in conduct, skin impacts, breathing, food, water consumption. No considerable weight loss was observed for all the animals [61].

**Subchronic toxicity:** Observed parameters for general signs are summarised in Table 2. Observed changes in toxicity study are noted in Fig. 6.

**Haematological and histopathological evaluation:** All the erythro and leuko parameters are shown in Table 3. Microscopic structural changes of the organ liver, kidneys and skin is shown in Fig. 6.

**General signs:** No harmful signs or mortality were seen in test animals. Animals did not show any critical change of conduct, skin impacts, breathing, food and water consumption, postural irregularities. The physical appearance of skin, fur and eyes was normal. The bodyweight of the rats
was found to be more. This indicated that applying the formulation on the skin had no effect on the growth. A proper intake of nutrients and water was observed.

|                          | Treatment female group | Treatment male Group | Placebo control female group | Placebo control male group |
|--------------------------|------------------------|----------------------|------------------------------|---------------------------|
| Skin                     |                        |                      |                              |                           |
| Heart                    |                        |                      |                              |                           |
| Kidney                   |                        |                      |                              |                           |
| Liver                    |                        |                      |                              |                           |
| Microscopic view of skin |                        |                      |                              |                           |
| Skin of animal at end of study |                    |                      |                              |                           |

Fig. 6. Organ histopathology for the repeat dose study
Table 2. General signs for acute and repeat dose toxicity

| Test parameter         | Acute toxicity |        |        | Repeat dose toxicity |        |        |
|------------------------|----------------|--------|--------|----------------------|--------|--------|
|                        | Treatment group | Control group | Treatment group | Control group | Treatment group | Control group |
| Skin, fur              | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Eyes                   | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Mucosa membrane        | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Salivation             | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Behavioural pattern    | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Lethargy               | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Sleep                  | No alteration  | No alteration | No alteration | No alteration | No alteration | No alteration |
| Diarrhoea              | No             | No       | No     | No                   | No     | No     |
| Tremors                | No             | No       | No     | No                   | No     | No     |
| Body weight            | Weight gain    | Weight gain | Weight gain | Weight gain | Weight gain | Weight gain |

Table 3. Evaluation of various haematological parameters for the repeat dose toxicity

| Group                  | Hb gm % | RBC $\times 10^6$ / cmm | WBC $\times 10^3$ / cmm | PLT $\times 10^3$ / cmm | PCV % | MCV fl | MCH pg | MCHC gm/dl | N % | E % | L % | M % |
|------------------------|---------|--------------------------|--------------------------|--------------------------|-------|--------|--------|-------------|-----|-----|-----|-----|
| Test group Female      | 16.0    | 9.13                     | 23.0                     | 762                      | 49.6  | 54.4   | 17.5   | 32.2        | 57  | 4   | 38  | 1   |
| Test group Male        | 16.1    | 8.84                     | 12.3                     | 623                      | 49.2  | 55.7   | 18.2   | 32.7        | 66  | 2   | 31  | 1   |
| Placebo control female | 15.4    | 8.48                     | 12.9                     | 655                      | 40.1  | 55.0   | 18.4   | 33.5        | 59  | 2   | 39  | 0   |
| Placebo control male   | 15.0    | 8.35                     | 13.6                     | 869                      | 43.0  | 51.5   | 17.9   | 34.8        | 68  | 0   | 32  | 0   |

Hb: Hemoglobin, RBC: Red Blood Cell, WBC: White Blood Cell, PLT: Platelets, PCV: Packed Cell Volume, MCV: Mean Corpuscular Volume, Retic: Reticulocyte, MCHC: Mean Corpuscular Hemoglobin Concentration, MCH: Mean Corpuscular Hemoglobin, N: Neutrophils, E: Eosinophils, L: Lymphocytes, M: Monocytes
Haematological evaluation: After 28 days of the treatment no significant changes in haematological and serum biochemistry parameters level were observed in control and treatment groups.

Histopathology examination: It shows in considerable variations in control and treatment groups. Hence, it is suggested that the formulation is non-toxic. Histo-pathological evaluation of organs indicated no structural damage to the selected organs.

Liver histology revealed no alteration in portal and central vein, bile duct and hepatic artery in the control and treated rats. There was no fibrosis, necrosis, inflammation, or local fatty degeneration in the liver hepatocytes. The kidney displayed no adverse effects. No morphological alteration was observed in cardiac muscles, arteries and veins. The microscopic examination of the skin of rats did not indicate any changes in the layers of the skin compared to the control group [62].

5. CONCLUSION

Both hydrophilic and lipophilic drug-loaded NLCs were prepared with Span 20, Oleic acid, Emuicier 61, Shea butter and Cremophor EL using homogenization-sonication method. The NLCs have more target potential to the topical part of the skin. NLCs were found to reduce the irritation potential and more efficacious in treatment for in vivo anti-acne study results. The results of the toxicity study suggest that formulation is with no death or no signs of toxicity at 2000 mg/kg (acute study) and 1000 mg/kg (repeat dose toxicity study), thus proving safety for use. The organ histology revealed no changes in both the groups and was considered safe since they did not induce dermal toxicity, irritation and sensitization. The results of the presented study suggest NLCs as improved nanocarriers for Tretinoin and clindamycin formulation as they offer many advantages over marketed gel.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The experimental protocols were approved by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and the Institutional Animal Ethics Committee (IAEC) of the institute (Protocol no: KMKMP/IAE/081718).

ACKNOWLEDGEMENT

The authors are thankful to the Department of Pharmaceutics of Prin. K. M. Kundnani College of Pharmacy, for laboratory support for the conduct of the work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846-50.
2. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18(9):489-99.
3. Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol. 2005;52(2): 207–14.
4. Harris HH, Downing DT, Stewart ME, Strauss JS. Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol. 1983;8(2):200-3.
5. Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immune histochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 1992;133(3):467-75.
6. Leyden JJ. New understanding of the pathogenesis of acne. J Am Acad Dermatol. 1995;32:515–25.
7. Plewig G, Kligman AM. Acne and Rosacea. 3rd ed. New York: Springer-Verlag; 2000.
8. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulthe A. Pathogenesis and pathogenesis-related treatment of acne. J Dermatol. 1991;18:489–99.
9. Zouboulis CC, Xia L, Akamatsu H, Seltmann H, Fritsch M, Hornemann S, et al. The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology. 1998;196(1):21-31.
10. Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 1):1–29.
11. Fynd O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica. 1986;172:263–7.
12. Krautheim A, Gollnick H. Acne; topical treatment. Clin Dermatol. 2004;22:398–407.
13. Jain S. Topical tretinoin or adapalene in acne vulgaris: An overview. J Dermatol Treat. 2004;15:200–07.
14. Kircik LH, Evaluating tretinoin formulations in the treatment of acne. J Drugs Dermatol 2014;13:466–70.
15. Johnson BA, Nunley JR. Topical therapy for acne vulgaris. How do you choose the best drug for each patient? Postgrad Med. 2000;107:73.
16. Shalita AR, Smith EB, Bauer E. Topical erythromycin vs clindamycin therapy for acne-A multicenter, double blind comparison. Arch Dermatol. 1984;120:351–55.
17. Sardesai VR, Kambli VM. Comparison of efficacy of topical clindamycin and nicotinamide combination with plain clindamycin for the treatment of acne vulgaris and acne resistant to topical antibiotics. Indian J Dermatol Venereol Leprol. 2003;69:138–9.
18. Müller RH, S. Runge, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-89.
19. Junghanns J, Müller RA. Nanocrystal technology: drug delivery and clinical applications. Int J Nanomed. 2008;3(3):295-310.
20. Narayan R, Singh A, Ranjan OP, Nayak Y, Garg S. Development of risperidone liposomes for brain targeting through intranasal route. Life Sci. 2016;163:38-45.
21. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev. 2013;659(1):36-48.
22. Gharbavi M, Amani J, Kheiri MH, Danafar H, Sharafi A. Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier. Advances in Pharmacol Sci. 2018;Article ID 6847971:1-15.
23. Singh PK, Iqubal MK, Shukla VK, Shuaib M. Microemulsions: Current trends in novel drug delivery systems. J of Pharm Chem and Bio Sci. 2014;1(1):39-51.
24. Battaglia L, Gallarate M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Del. 2012;9(5):497–508.
25. Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Del. 2015;22(6):691–700.
26. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Cont Rel. 2017;264:306–32.
27. Naseri N, Valizadeh H, Milani PZ. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–13.
28. Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Stefano AD. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13(8):1121–31.
29. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticle. Int J Nanomed. 2007;2(4):595–07.
30. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS. 2011;12 (1):62–76.
31. Weber S, ZimmerA, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(2):7–22.

32. Iqbal MA, Sahni JK, Baboota S. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug. Target. 2012;20(10):813–30.

33. Pardeike J, Hommos A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170–84.

34. Surekha, P. et al. Repeated dose dermal toxicity study of nano zinc oxide with Sprague-Dawley rats. Cutan Ocul Toxicol. 2011;21:26–32.

35. OECD. OECD Guideline for Testing of Chemicals: Acute Dermal Toxicity. France: OECD. 1987; 402.

36. OECD. OECD Guideline for Testing of Chemicals: Repeat dose toxicity dermal irritation/corrosion. France: OECD. 2002;404.

37. Abbaspour M, BSMahmalzadeh, Alireza Jahangiri ZA, Shiralipour R. Effect of anionic polymers on drug loading and release from clindamycin phosphate solid lipid nanoparticles. Tropical J of Pharm Res August. 2013;12(4):477-82.

38. Tehrani MB, Namadchian M, Vatan SF, Souri1 E. Derivative spectrophotometric method for simultaneous determination of clindamycin phosphate and tretinoin in pharmaceutical dosage forms. DARU J of Pharm Sci. 2013;21:29-35.

39. EL Yazbi FA, Blaih SM. Spectrophotometric and titrimetric determination of clindamycin hydrochloride in pharmaceutical preparations. Analyst. 1993;118:577–79.

40. Gupta A, Gulati M, Pandey NK. A validated UV spectrophotometric method for simultaneous estimation of tretinoin and benzoyl peroxide in bulk and semisolid dosage form. Rasayan J Chem. 2009;2(3):649–54.

41. Patel P, Kabra P, Kimbahune R, Urmila GH Quantitative estimation of isotretinoin in bulk and formulation by UV-visible spectrophotometry. Res J Pharm Biol Chem Sci. 2011;2(1):167–72.

42. Ennas VG, Manconi M, Sinico C, Marongiu F, Scano A, Fadda AM. Liposomes for (trans)dermal delivery of tretinoin: influence of drug concentration and vesicle composition. J Drug Deliv Sci Technol. 2015;18:309–13.

43. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363:132–38.

44. Qianwen L, Tiange C, Yinghong H, Xia X, Susan PC, Cai Y. A review of the structure, preparation, and application of NLCS, PNPS, and PLNS. Nanomaterials. 2017;7:122-34.

45. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS. 2011;12 (1):62–76.

46. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86 (2):7-22.

47. Khosaa A, Reddia S, Ranendra NS. Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy. 2018;103:598–613.

48. Uner M. Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. Handbook of Nanoparticles, Springer International Publishing. 2016;117–141.

49. Zheng M, Falkeborg M, Zheng Y, Yang T. Formulation and characterization of nanostructured lipid carriers containing a mixed lipids core. Colloids Surf A Physicochem Eng Asp. 2013;430: 76–84.

50. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633–40.

51. Chen Y, Yang X, Zhao L, Almasy L, Garamus VM. Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug. Colloids Surf A Physicochem Eng Asp. 2014;455:36–43.

52. Fang CL, Al Suwayeh SA. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7(1): 41–55.

53. Desai PP, Date AA, Patravale V. Overcoming poor oral bioavailability using nano-particle formulations – opportunities and limitations. Drug Discov Today Technol. 2012;(2):87–95.
54. Teeranachaideekul V, Boonme P, Souto EB. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Con Rel. 2008;128(2):134–41.
55. Zhao J, Piao X, Shi X, Si A, Zhang Y, Feng N. Podophyllotoxin-loaded nanostructured lipid carriers for skin targeting: in vitro and in vivo studies. Molecules. 2016; 21(11):15–49.
56. Han R, Yin X, Che J, Yuan Y, Cui H. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 2012;439(1):349–57.
57. Uprit S, Sahu RK, Amit Roy A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 2013;21(4):379–385.
58. Monteiro-Riviere NA, Wiench K, Landsiedel R, Schulte S, Inman AO, Riviere JE. Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study. Toxicol Sci. 2011;123(1):264–80.
59. Pinheiro M, Ribeiro R, Vieira A, Andrade F, Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Design, Development and Therapy . 2016;10:2467–2475
60. Mirshahpanah P, Maibach HI. Models in acnegenesis. Cut Ocul Toxicol. 2007;26:195–202.
61. Harizal SN, Mansor SM, Hasnan J, Tharakan, JK, Abdullah, J. Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in Rodent. J Ethnopharmacol. 2010;131:404–9.
62. Rhiouania H, El-Hilalya J, Israili ZH, Lyoussia B. Acute and subchronic toxicity of an aqueous extract of the leaves of Herniaria glabra in rodents. J. Ethnopharmacol. 2008;118:378–86.

© 2021 Lala and Nandvikar; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/72512